Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study

Background Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens. The objective of this study was to evaluate the antibacterial activity of omadacycline against recently collected...

Full description

Saved in:
Bibliographic Details
Published inBMC microbiology Vol. 20; no. 1; pp. 350 - 9
Main Authors Xiao, Meng, Huang, Jing-jing, Zhang, Ge, Yang, Wen-hang, Kong, Fanrong, Kudinha, Timothy, Xu, Ying-chun
Format Journal Article
LanguageEnglish
Published London BioMed Central 16.11.2020
BioMed Central Ltd
Springer Nature B.V
BMC
Subjects
Aminomethylcycline
Antibacterial activity
Antibiotics
Antimicrobial activity
Antimicrobial agents
Bacteria
Bacterial infections
Biological Microscopy
Biomedical and Life Sciences
Clinical microbiology and vaccines
Drug resistance
Drug therapy
E coli
FDA approval
Genotype & phenotype
Gram-negative bacteria
Infectious diseases
Life Sciences
Methicillin
Microbiology
Minocycline
Mycology
Omadacycline
Parasitology
Pathogens
Patient outcomes
Penicillin
Pharmacological research
Pneumonia
Research Article
Staphylococcus aureus
Staphylococcus infections
Streptococcus infections
Streptococcus pneumoniae
Surveillance
Tetracyclines
Virology
China
United States > US
Tetracyclines
Omadacycline
Aminomethylcycline
Staphylococcus aureus
Streptococcus pneumoniae
Online AccessGet full text
ISSN1471-2180
1471-2180
DOI10.1186/s12866-020-02019-8

Cover

Abstract Background Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens. The objective of this study was to evaluate the antibacterial activity of omadacycline against recently collected bacterial isolates from Chinese patients. Results Omadacycline showed potent activity against all Gram-positive pathogens: S. aureus MICs were low regardless of susceptibility to methicillin (methicillin-resistant Staphylococcus aureus , MRSA: N  = 97, MIC 50/90 0.12/0.25 mg/L, 98.5% susceptible; methicillin-sensitive Staphylococcus aureus , MSSA: N  = 100, MIC 50/90 0.12/0.12 mg/L, 100.0% susceptible). Omadacycline was also very effective against β-haemolytic streptococci (MIC 50/90 , 0.06/0.12 mg/L), viridans group streptococci (MIC 50/90 ,<0.03/0. 06 mg/L), and enterococci (MIC 50/90 , 0.03/0.12 mg/L). Against S. pneumoniae , omadacycline was highly active regardless of penicillin-resistance (MIC 90 0.06 mg/L) and despite the fact that less than 10.0% of these strains were susceptible to tetracycline. Omadacycline exhibited good in vitro activity against Enterobacterales isolates (MIC 50/90 , 2/8 mg/L), inhibiting 81.7% of the isolates at ≤4 mg/L. M. catarrhalis isolates (MIC 50/90 , 0.12/0.25 mg/L) were fully susceptible to omadacycline at ≤0.5 mg/L. Conclusions Omadacycline showed potent in vitro activity against most common bacterial pathogens, and even against highly resistant problem pathogens, such as MRSA, penicillin-R and tetracycline-R S. pneumoniae and enterococci. The susceptibility rate of Chinese isolates was similar to those reported in other countries, but the decreased activity against K. pneumoniae isolates in the present study should be noted.
AbstractList Abstract Background Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens. The objective of this study was to evaluate the antibacterial activity of omadacycline against recently collected bacterial isolates from Chinese patients. Results Omadacycline showed potent activity against all Gram-positive pathogens: S. aureus MICs were low regardless of susceptibility to methicillin (methicillin-resistant Staphylococcus aureus, MRSA: N = 97, MIC50/90 0.12/0.25 mg/L, 98.5% susceptible; methicillin-sensitive Staphylococcus aureus, MSSA: N = 100, MIC50/90 0.12/0.12 mg/L, 100.0% susceptible). Omadacycline was also very effective against β-haemolytic streptococci (MIC50/90, 0.06/0.12 mg/L), viridans group streptococci (MIC50/90,<0.03/0. 06 mg/L), and enterococci (MIC50/90, 0.03/0.12 mg/L). Against S. pneumoniae, omadacycline was highly active regardless of penicillin-resistance (MIC90 0.06 mg/L) and despite the fact that less than 10.0% of these strains were susceptible to tetracycline. Omadacycline exhibited good in vitro activity against Enterobacterales isolates (MIC50/90, 2/8 mg/L), inhibiting 81.7% of the isolates at ≤4 mg/L. M. catarrhalis isolates (MIC50/90, 0.12/0.25 mg/L) were fully susceptible to omadacycline at ≤0.5 mg/L. Conclusions Omadacycline showed potent in vitro activity against most common bacterial pathogens, and even against highly resistant problem pathogens, such as MRSA, penicillin-R and tetracycline-R S. pneumoniae and enterococci. The susceptibility rate of Chinese isolates was similar to those reported in other countries, but the decreased activity against K. pneumoniae isolates in the present study should be noted.
Background Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens. The objective of this study was to evaluate the antibacterial activity of omadacycline against recently collected bacterial isolates from Chinese patients. Results Omadacycline showed potent activity against all Gram-positive pathogens: S. aureus MICs were low regardless of susceptibility to methicillin (methicillin-resistant Staphylococcus aureus , MRSA: N  = 97, MIC 50/90 0.12/0.25 mg/L, 98.5% susceptible; methicillin-sensitive Staphylococcus aureus , MSSA: N  = 100, MIC 50/90 0.12/0.12 mg/L, 100.0% susceptible). Omadacycline was also very effective against β-haemolytic streptococci (MIC 50/90 , 0.06/0.12 mg/L), viridans group streptococci (MIC 50/90 ,<0.03/0. 06 mg/L), and enterococci (MIC 50/90 , 0.03/0.12 mg/L). Against S. pneumoniae , omadacycline was highly active regardless of penicillin-resistance (MIC 90 0.06 mg/L) and despite the fact that less than 10.0% of these strains were susceptible to tetracycline. Omadacycline exhibited good in vitro activity against Enterobacterales isolates (MIC 50/90 , 2/8 mg/L), inhibiting 81.7% of the isolates at ≤4 mg/L. M. catarrhalis isolates (MIC 50/90 , 0.12/0.25 mg/L) were fully susceptible to omadacycline at ≤0.5 mg/L. Conclusions Omadacycline showed potent in vitro activity against most common bacterial pathogens, and even against highly resistant problem pathogens, such as MRSA, penicillin-R and tetracycline-R S. pneumoniae and enterococci. The susceptibility rate of Chinese isolates was similar to those reported in other countries, but the decreased activity against K. pneumoniae isolates in the present study should be noted.
Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens. The objective of this study was to evaluate the antibacterial activity of omadacycline against recently collected bacterial isolates from Chinese patients.BACKGROUNDOmadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens. The objective of this study was to evaluate the antibacterial activity of omadacycline against recently collected bacterial isolates from Chinese patients.Omadacycline showed potent activity against all Gram-positive pathogens: S. aureus MICs were low regardless of susceptibility to methicillin (methicillin-resistant Staphylococcus aureus, MRSA: N = 97, MIC50/90 0.12/0.25 mg/L, 98.5% susceptible; methicillin-sensitive Staphylococcus aureus, MSSA: N = 100, MIC50/90 0.12/0.12 mg/L, 100.0% susceptible). Omadacycline was also very effective against β-haemolytic streptococci (MIC50/90, 0.06/0.12 mg/L), viridans group streptococci (MIC50/90,<0.03/0. 06 mg/L), and enterococci (MIC50/90, 0.03/0.12 mg/L). Against S. pneumoniae, omadacycline was highly active regardless of penicillin-resistance (MIC90 0.06 mg/L) and despite the fact that less than 10.0% of these strains were susceptible to tetracycline. Omadacycline exhibited good in vitro activity against Enterobacterales isolates (MIC50/90, 2/8 mg/L), inhibiting 81.7% of the isolates at ≤4 mg/L. M. catarrhalis isolates (MIC50/90, 0.12/0.25 mg/L) were fully susceptible to omadacycline at ≤0.5 mg/L.RESULTSOmadacycline showed potent activity against all Gram-positive pathogens: S. aureus MICs were low regardless of susceptibility to methicillin (methicillin-resistant Staphylococcus aureus, MRSA: N = 97, MIC50/90 0.12/0.25 mg/L, 98.5% susceptible; methicillin-sensitive Staphylococcus aureus, MSSA: N = 100, MIC50/90 0.12/0.12 mg/L, 100.0% susceptible). Omadacycline was also very effective against β-haemolytic streptococci (MIC50/90, 0.06/0.12 mg/L), viridans group streptococci (MIC50/90,<0.03/0. 06 mg/L), and enterococci (MIC50/90, 0.03/0.12 mg/L). Against S. pneumoniae, omadacycline was highly active regardless of penicillin-resistance (MIC90 0.06 mg/L) and despite the fact that less than 10.0% of these strains were susceptible to tetracycline. Omadacycline exhibited good in vitro activity against Enterobacterales isolates (MIC50/90, 2/8 mg/L), inhibiting 81.7% of the isolates at ≤4 mg/L. M. catarrhalis isolates (MIC50/90, 0.12/0.25 mg/L) were fully susceptible to omadacycline at ≤0.5 mg/L.Omadacycline showed potent in vitro activity against most common bacterial pathogens, and even against highly resistant problem pathogens, such as MRSA, penicillin-R and tetracycline-R S. pneumoniae and enterococci. The susceptibility rate of Chinese isolates was similar to those reported in other countries, but the decreased activity against K. pneumoniae isolates in the present study should be noted.CONCLUSIONSOmadacycline showed potent in vitro activity against most common bacterial pathogens, and even against highly resistant problem pathogens, such as MRSA, penicillin-R and tetracycline-R S. pneumoniae and enterococci. The susceptibility rate of Chinese isolates was similar to those reported in other countries, but the decreased activity against K. pneumoniae isolates in the present study should be noted.
Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens. The objective of this study was to evaluate the antibacterial activity of omadacycline against recently collected bacterial isolates from Chinese patients. Omadacycline showed potent activity against all Gram-positive pathogens: S. aureus MICs were low regardless of susceptibility to methicillin (methicillin-resistant Staphylococcus aureus, MRSA: N = 97, MIC 0.12/0.25 mg/L, 98.5% susceptible; methicillin-sensitive Staphylococcus aureus, MSSA: N = 100, MIC 0.12/0.12 mg/L, 100.0% susceptible). Omadacycline was also very effective against β-haemolytic streptococci (MIC , 0.06/0.12 mg/L), viridans group streptococci (MIC ,<0.03/0. 06 mg/L), and enterococci (MIC , 0.03/0.12 mg/L). Against S. pneumoniae, omadacycline was highly active regardless of penicillin-resistance (MIC 0.06 mg/L) and despite the fact that less than 10.0% of these strains were susceptible to tetracycline. Omadacycline exhibited good in vitro activity against Enterobacterales isolates (MIC , 2/8 mg/L), inhibiting 81.7% of the isolates at ≤4 mg/L. M. catarrhalis isolates (MIC , 0.12/0.25 mg/L) were fully susceptible to omadacycline at ≤0.5 mg/L. Omadacycline showed potent in vitro activity against most common bacterial pathogens, and even against highly resistant problem pathogens, such as MRSA, penicillin-R and tetracycline-R S. pneumoniae and enterococci. The susceptibility rate of Chinese isolates was similar to those reported in other countries, but the decreased activity against K. pneumoniae isolates in the present study should be noted.
Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens. The objective of this study was to evaluate the antibacterial activity of omadacycline against recently collected bacterial isolates from Chinese patients. Omadacycline showed potent activity against all Gram-positive pathogens: S. aureus MICs were low regardless of susceptibility to methicillin (methicillin-resistant Staphylococcus aureus, MRSA: N = 97, MIC.sub.50/90 0.12/0.25 mg/L, 98.5% susceptible; methicillin-sensitive Staphylococcus aureus, MSSA: N = 100, MIC.sub.50/90 0.12/0.12 mg/L, 100.0% susceptible). Omadacycline was also very effective against [beta]-haemolytic streptococci (MIC.sub.50/90, 0.06/0.12 mg/L), viridans group streptococci (MIC.sub.50/90,<0.03/0. 06 mg/L), and enterococci (MIC.sub.50/90, 0.03/0.12 mg/L). Against S. pneumoniae, omadacycline was highly active regardless of penicillin-resistance (MIC.sub.90 0.06 mg/L) and despite the fact that less than 10.0% of these strains were susceptible to tetracycline. Omadacycline exhibited good in vitro activity against Enterobacterales isolates (MIC.sub.50/90, 2/8 mg/L), inhibiting 81.7% of the isolates at [less than or equai to]4 mg/L. M. catarrhalis isolates (MIC.sub.50/90, 0.12/0.25 mg/L) were fully susceptible to omadacycline at [less than or equai to]0.5 mg/L. Omadacycline showed potent in vitro activity against most common bacterial pathogens, and even against highly resistant problem pathogens, such as MRSA, penicillin-R and tetracycline-R S. pneumoniae and enterococci. The susceptibility rate of Chinese isolates was similar to those reported in other countries, but the decreased activity against K. pneumoniae isolates in the present study should be noted.
Background Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens. The objective of this study was to evaluate the antibacterial activity of omadacycline against recently collected bacterial isolates from Chinese patients. Results Omadacycline showed potent activity against all Gram-positive pathogens: S. aureus MICs were low regardless of susceptibility to methicillin (methicillin-resistant Staphylococcus aureus, MRSA: N = 97, MIC50/90 0.12/0.25 mg/L, 98.5% susceptible; methicillin-sensitive Staphylococcus aureus, MSSA: N = 100, MIC50/90 0.12/0.12 mg/L, 100.0% susceptible). Omadacycline was also very effective against β-haemolytic streptococci (MIC50/90, 0.06/0.12 mg/L), viridans group streptococci (MIC50/90,<0.03/0. 06 mg/L), and enterococci (MIC50/90, 0.03/0.12 mg/L). Against S. pneumoniae, omadacycline was highly active regardless of penicillin-resistance (MIC90 0.06 mg/L) and despite the fact that less than 10.0% of these strains were susceptible to tetracycline. Omadacycline exhibited good in vitro activity against Enterobacterales isolates (MIC50/90, 2/8 mg/L), inhibiting 81.7% of the isolates at ≤4 mg/L. M. catarrhalis isolates (MIC50/90, 0.12/0.25 mg/L) were fully susceptible to omadacycline at ≤0.5 mg/L. Conclusions Omadacycline showed potent in vitro activity against most common bacterial pathogens, and even against highly resistant problem pathogens, such as MRSA, penicillin-R and tetracycline-R S. pneumoniae and enterococci. The susceptibility rate of Chinese isolates was similar to those reported in other countries, but the decreased activity against K. pneumoniae isolates in the present study should be noted.
Background Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens. The objective of this study was to evaluate the antibacterial activity of omadacycline against recently collected bacterial isolates from Chinese patients. Results Omadacycline showed potent activity against all Gram-positive pathogens: S. aureus MICs were low regardless of susceptibility to methicillin (methicillin-resistant Staphylococcus aureus, MRSA: N = 97, MIC.sub.50/90 0.12/0.25 mg/L, 98.5% susceptible; methicillin-sensitive Staphylococcus aureus, MSSA: N = 100, MIC.sub.50/90 0.12/0.12 mg/L, 100.0% susceptible). Omadacycline was also very effective against [beta]-haemolytic streptococci (MIC.sub.50/90, 0.06/0.12 mg/L), viridans group streptococci (MIC.sub.50/90,<0.03/0. 06 mg/L), and enterococci (MIC.sub.50/90, 0.03/0.12 mg/L). Against S. pneumoniae, omadacycline was highly active regardless of penicillin-resistance (MIC.sub.90 0.06 mg/L) and despite the fact that less than 10.0% of these strains were susceptible to tetracycline. Omadacycline exhibited good in vitro activity against Enterobacterales isolates (MIC.sub.50/90, 2/8 mg/L), inhibiting 81.7% of the isolates at [less than or equai to]4 mg/L. M. catarrhalis isolates (MIC.sub.50/90, 0.12/0.25 mg/L) were fully susceptible to omadacycline at [less than or equai to]0.5 mg/L. Conclusions Omadacycline showed potent in vitro activity against most common bacterial pathogens, and even against highly resistant problem pathogens, such as MRSA, penicillin-R and tetracycline-R S. pneumoniae and enterococci. The susceptibility rate of Chinese isolates was similar to those reported in other countries, but the decreased activity against K. pneumoniae isolates in the present study should be noted. Keywords: Omadacycline, Aminomethylcycline, Tetracyclines, Streptococcus pneumoniae, Staphylococcus aureus
ArticleNumber 350
Audience Academic
Author Zhang, Ge
Xiao, Meng
Huang, Jing-jing
Yang, Wen-hang
Xu, Ying-chun
Kudinha, Timothy
Kong, Fanrong
Author_xml – sequence: 1
  givenname: Meng
  surname: Xiao
  fullname: Xiao, Meng
  organization: Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases, Graduate School, Peking Union Medical College, Chinese academy of Medical Science
– sequence: 2
  givenname: Jing-jing
  surname: Huang
  fullname: Huang, Jing-jing
  organization: Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases, Graduate School, Peking Union Medical College, Chinese academy of Medical Science
– sequence: 3
  givenname: Ge
  surname: Zhang
  fullname: Zhang, Ge
  organization: Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases
– sequence: 4
  givenname: Wen-hang
  surname: Yang
  fullname: Yang, Wen-hang
  organization: Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases
– sequence: 5
  givenname: Fanrong
  surname: Kong
  fullname: Kong, Fanrong
  organization: Centre for Infectious Diseases and Microbiology Laboratory Services, ICPMR-Pathology West, Westmead Hospital
– sequence: 6
  givenname: Timothy
  surname: Kudinha
  fullname: Kudinha, Timothy
  organization: Charles Sturt University, NSW Health Pathology, Regional and Rural, Orange Hospital
– sequence: 7
  givenname: Ying-chun
  surname: Xu
  fullname: Xu, Ying-chun
  email: xycpumch@139.com
  organization: Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33198626$$D View this record in MEDLINE/PubMed
BookMark eNqNUl2L1DAULbLifugf8EECvijYtUnaJH1ZGAY_BhYEP57DbZrOZmiTMUlXx19vOjOuM4ssUkrK7Tnn5p5zz7MT66zOsue4uMRYsLcBE8FYXpBienGdi0fZGS45zgkWxcnB92l2HsKqKDAXlD_JTinFtWCEnWW_ZjaawSjvGgM9AhXNrYkb5DrkBmhBbVRvrEbGolT3DsESjA0RNQmqvQFkgush6hZ13g0o3aNE0U0nn0jzG2PhDQI0jH00udI2sVCIY7t5mj3uoA_62f68yL69f_d1_jG__vRhMZ9d54qVOOaK64LxqmOlqIBRVneNqhTvsMANrhkjhOqKV0SRVpWCd5Uou6qhRU2qkoOq6UW22Om2DlZy7c0AfiMdGLktOL-U4KNRvZYVL0pFaUNb0Za4EyJ1oLzRtKqTW0CSFt1pjXYNmx_Q93eCuJBTKnKXikyJyG0qUiTW1Y61HptBt5MJHvqjqxz_seZGLt2t5IxxXvIk8Gov4N33UYcoBxOU7nuw2o1BkpJhWlcVm3q9vAddudHbZPAWJRIIH6CWkMY2tnOpr5pE5YyVJE0g6mnay3-g0tPqtDJpGTuT6keE10eEhIn6Z1zCGIJcfPl8jH1xaMqdG392MwHEDpCWMwSvO6lMhGjc5JHpHzac3KP-V0r7bEMC26X2f517gPUbzDsTig
CitedBy_id crossref_primary_10_1007_s40121_024_01065_3
crossref_primary_10_2147_IDR_S352932
crossref_primary_10_1128_jcm_00843_21
crossref_primary_10_1089_mdr_2024_0215
crossref_primary_10_3390_antibiotics12050910
crossref_primary_10_1080_14787210_2023_2151435
crossref_primary_10_1016_j_ijantimicag_2021_106377
crossref_primary_10_1016_j_biopha_2024_117666
crossref_primary_10_1093_milmed_usad417
crossref_primary_10_1038_s44222_024_00250_w
crossref_primary_10_1080_07853890_2022_2085881
crossref_primary_10_3389_fphar_2022_869237
crossref_primary_10_2147_IDR_S500982
crossref_primary_10_3390_antibiotics12060953
crossref_primary_10_1080_1120009X_2022_2095156
crossref_primary_10_3390_molecules28041762
crossref_primary_10_1186_s12879_023_08212_0
crossref_primary_10_3389_fmicb_2022_1043736
Cites_doi 10.1055/s-0036-1592075
10.1128/AAC.01242-13
10.1016/j.rmed.2019.10.006
10.1016/j.diagmicrobio.2010.05.012
10.1093/cid/ciz395
10.1136/bmjopen-2017-018709
10.1093/cid/ciz396
10.1128/AAC.01734-16
10.1371/journal.pone.0223599
10.1016/S1473-3099(18)30296-2
10.1128/AAC.02262-18
10.1592/phco.27.7.980
10.1128/AAC.00470-19
10.1093/cid/ciu508
10.1186/1749-7922-9-57
10.1002/jmv.24963
10.1016/j.chest.2017.04.162
10.1179/joc.2007.19.6.753
10.1586/14787210.2015.1023291
10.3389/fmicb.2019.02546
10.1093/jac/dkr561
10.2147/IDR.S213296
10.1097/INF.0000000000001753
10.1001/jama.2010.1115
10.2217/fmb-2016-0100
10.1056/NEJMoa1800201
10.1016/j.jgar.2019.02.017
10.1128/AAC.01414-09
10.1016/j.bmc.2016.07.029
10.1128/AAC.01536-15
ContentType Journal Article
Copyright The Author(s) 2020
COPYRIGHT 2020 BioMed Central Ltd.
2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2020
– notice: COPYRIGHT 2020 BioMed Central Ltd.
– notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
ISR
3V.
7QL
7T7
7U9
7X7
7XB
88E
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7N
M7P
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.1186/s12866-020-02019-8
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Industrial and Applied Microbiology Abstracts (Microbiology A)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
PubMed


Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1471-2180
EndPage 9
ExternalDocumentID oai_doaj_org_article_5704c33b3d8d41f88b1937be359626a2
10.1186/s12866-020-02019-8
PMC7667747
A642286892
33198626
10_1186_s12866_020_02019_8
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations China
United States--US
GeographicLocations_xml – name: China
– name: United States--US
GrantInformation_xml – fundername: Tsinghua University-Peking Union Medical College Hospital
  grantid: PTQH201911583
– fundername: National Major Science and Technology Projects of China
  grantid: 2017ZX10103004
  funderid: http://dx.doi.org/10.13039/501100013076
– fundername: National Major Science and Technology Projects of China
  grantid: 2017ZX10103004
– fundername: ;
  grantid: 2017ZX10103004
– fundername: ;
  grantid: PTQH201911583
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
7X7
88E
8FE
8FH
8FI
8FJ
A8Z
AAFWJ
AAJSJ
AASML
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESTFP
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IGS
IHR
INH
INR
ISR
ITC
KQ8
LK5
LK8
M1P
M48
M7P
M7R
MM.
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
~02
AAYXX
CITATION
-A0
3V.
ACRMQ
ADINQ
AGJBV
ALIPV
C24
NPM
7QL
7T7
7U9
7XB
8FD
8FK
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
M7N
P64
PKEHL
PQEST
PQUKI
7X8
5PM
2VQ
4.4
ADTOC
AHSBF
C1A
EJD
H13
IPNFZ
RIG
UNPAY
ID FETCH-LOGICAL-c641t-c7e0675f6485a6369fbc5c7f181b1966223e5752c2dc487f584f5b3092547ac93
IEDL.DBID M48
ISSN 1471-2180
IngestDate Fri Oct 03 12:52:42 EDT 2025
Sun Oct 26 04:02:10 EDT 2025
Tue Sep 30 16:39:10 EDT 2025
Fri Sep 05 08:36:00 EDT 2025
Wed Oct 08 14:21:22 EDT 2025
Mon Oct 20 22:16:05 EDT 2025
Mon Oct 20 16:13:41 EDT 2025
Thu Oct 16 13:56:03 EDT 2025
Wed Feb 19 02:28:49 EST 2025
Wed Oct 01 05:10:31 EDT 2025
Thu Apr 24 23:06:01 EDT 2025
Sat Sep 06 07:28:44 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Tetracyclines
Omadacycline
Aminomethylcycline
Staphylococcus aureus
Streptococcus pneumoniae
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c641t-c7e0675f6485a6369fbc5c7f181b1966223e5752c2dc487f584f5b3092547ac93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12866-020-02019-8
PMID 33198626
PQID 2461855618
PQPubID 42585
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_5704c33b3d8d41f88b1937be359626a2
unpaywall_primary_10_1186_s12866_020_02019_8
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7667747
proquest_miscellaneous_2461395568
proquest_journals_2461855618
gale_infotracmisc_A642286892
gale_infotracacademiconefile_A642286892
gale_incontextgauss_ISR_A642286892
pubmed_primary_33198626
crossref_citationtrail_10_1186_s12866_020_02019_8
crossref_primary_10_1186_s12866_020_02019_8
springer_journals_10_1186_s12866_020_02019_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-11-16
PublicationDateYYYYMMDD 2020-11-16
PublicationDate_xml – month: 11
  year: 2020
  text: 2020-11-16
  day: 16
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle BMC microbiology
PublicationTitleAbbrev BMC Microbiol
PublicationTitleAlternate BMC Microbiol
PublicationYear 2020
Publisher BioMed Central
BioMed Central Ltd
Springer Nature B.V
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: Springer Nature B.V
– name: BMC
References A Chatterjee (2019_CR4) 2018; 18
R Serra (2019_CR22) 2015; 13
SK Tanaka (2019_CR13) 2016; 24
JA Karlowsky (2019_CR31) 2019; 69
YS Kwon (2019_CR6) 2019; 158
MD Huband (2019_CR10) 2019; 19
KB Waites (2019_CR15) 2016; 60
AJ Kallen (2019_CR19) 2010; 304
R Stets (2019_CR8) 2019; 380
CG Carvalhaes (2019_CR16) 2019; 63
L Honeyman (2019_CR12) 2015; 59
RE Corrado (2019_CR1) 2017; 152
2019_CR35
2019_CR33
M Wu (2019_CR11) 2019; 14
JJ Schafer (2019_CR29) 2007; 27
AT Freire (2019_CR28) 2010; 68
2019_CR21
EUCAST (2019_CR34) 2019
A Kaushik (2019_CR14) 2019; 63
AP Johnson (2019_CR18) 2012; 67
JH Song (2019_CR2) 2016; 37
2019_CR27
M Sartelli (2019_CR23) 2014; 9
BA Cunha (2019_CR30) 2007; 19
L Chen (2019_CR25) 2018; 8
B Bai (2019_CR26) 2019; 10
S Villano (2019_CR32) 2016; 11
H Oumei (2019_CR24) 2018; 90
BG Mitchell (2019_CR20) 2014; 59
KG Hulten (2019_CR17) 2018; 37
CM Rubino (2019_CR5) 2010; 54
J Chen (2019_CR3) 2019; 12
FM Abrahamian (2019_CR7) 2019; 69
AB Macone (2019_CR9) 2014; 58
References_xml – volume: 37
  start-page: 839
  issue: 6
  year: 2016
  ident: 2019_CR2
  publication-title: Semin Resp Crit Care
  doi: 10.1055/s-0036-1592075
– volume: 58
  start-page: 1127
  issue: 2
  year: 2014
  ident: 2019_CR9
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01242-13
– volume: 158
  start-page: 89
  year: 2019
  ident: 2019_CR6
  publication-title: Resp Med
  doi: 10.1016/j.rmed.2019.10.006
– volume: 68
  start-page: 140
  issue: 2
  year: 2010
  ident: 2019_CR28
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2010.05.012
– volume: 69
  start-page: S6
  issue: Supplement_1
  year: 2019
  ident: 2019_CR31
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciz395
– volume: 8
  issue: 2
  year: 2018
  ident: 2019_CR25
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2017-018709
– volume: 69
  start-page: S23
  issue: Supplement_1
  year: 2019
  ident: 2019_CR7
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciz396
– volume: 60
  start-page: 7502
  issue: 12
  year: 2016
  ident: 2019_CR15
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01734-16
– volume: 14
  issue: 10
  year: 2019
  ident: 2019_CR11
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0223599
– ident: 2019_CR21
– ident: 2019_CR27
– volume: 18
  start-page: e368
  issue: 12
  year: 2018
  ident: 2019_CR4
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(18)30296-2
– volume: 63
  start-page: e02262
  issue: 3
  year: 2019
  ident: 2019_CR16
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.02262-18
– volume: 27
  start-page: 980
  issue: 7
  year: 2007
  ident: 2019_CR29
  publication-title: Pharmacotherapy.
  doi: 10.1592/phco.27.7.980
– volume: 63
  start-page: e00470
  issue: 6
  year: 2019
  ident: 2019_CR14
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00470-19
– volume: 59
  start-page: 969
  issue: 7
  year: 2014
  ident: 2019_CR20
  publication-title: Clin Infect
  doi: 10.1093/cid/ciu508
– ident: 2019_CR35
– volume: 9
  start-page: 57
  issue: 1
  year: 2014
  ident: 2019_CR23
  publication-title: World J Emerg Surg
  doi: 10.1186/1749-7922-9-57
– volume: 90
  start-page: 421
  issue: 3
  year: 2018
  ident: 2019_CR24
  publication-title: J Med Virol
  doi: 10.1002/jmv.24963
– ident: 2019_CR33
– volume: 152
  start-page: 930
  issue: 5
  year: 2017
  ident: 2019_CR1
  publication-title: Chest.
  doi: 10.1016/j.chest.2017.04.162
– volume: 19
  start-page: 753
  issue: 6
  year: 2007
  ident: 2019_CR30
  publication-title: J Chemother
  doi: 10.1179/joc.2007.19.6.753
– volume: 13
  start-page: 605
  issue: 5
  year: 2015
  ident: 2019_CR22
  publication-title: Expert Rev Anti-Infect Ther
  doi: 10.1586/14787210.2015.1023291
– volume: 10
  start-page: 2546
  year: 2019
  ident: 2019_CR26
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2019.02546
– volume: 67
  start-page: 802
  issue: 4
  year: 2012
  ident: 2019_CR18
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkr561
– volume-title: Breakpoint tables for interpretation of MICs and zone diameters, version 9.0
  year: 2019
  ident: 2019_CR34
– volume: 12
  start-page: 2335
  year: 2019
  ident: 2019_CR3
  publication-title: Infect Drug Resist
  doi: 10.2147/IDR.S213296
– volume: 37
  start-page: 235
  issue: 3
  year: 2018
  ident: 2019_CR17
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/INF.0000000000001753
– volume: 304
  start-page: 641
  issue: 6
  year: 2010
  ident: 2019_CR19
  publication-title: Jama.
  doi: 10.1001/jama.2010.1115
– volume: 11
  start-page: 1421
  year: 2016
  ident: 2019_CR32
  publication-title: Future Microbiol
  doi: 10.2217/fmb-2016-0100
– volume: 380
  start-page: 517
  issue: 6
  year: 2019
  ident: 2019_CR8
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1800201
– volume: 19
  start-page: 56
  year: 2019
  ident: 2019_CR10
  publication-title: J Glob Antimicrob Resist
  doi: 10.1016/j.jgar.2019.02.017
– volume: 54
  start-page: 5180
  issue: 12
  year: 2010
  ident: 2019_CR5
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01414-09
– volume: 24
  start-page: 6409
  issue: 24
  year: 2016
  ident: 2019_CR13
  publication-title: Bioorg Med Chem
  doi: 10.1016/j.bmc.2016.07.029
– volume: 59
  start-page: 7044
  issue: 11
  year: 2015
  ident: 2019_CR12
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01536-15
SSID ssj0017837
Score 2.4027886
Snippet Background Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative...
Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and...
Background Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative...
Abstract Background Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and...
SourceID doaj
unpaywall
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 350
SubjectTerms Aminomethylcycline
Antibacterial activity
Antibiotics
Antimicrobial activity
Antimicrobial agents
Bacteria
Bacterial infections
Biological Microscopy
Biomedical and Life Sciences
Clinical microbiology and vaccines
Drug resistance
Drug therapy
E coli
FDA approval
Genotype & phenotype
Gram-negative bacteria
Infectious diseases
Life Sciences
Methicillin
Microbiology
Minocycline
Mycology
Omadacycline
Parasitology
Pathogens
Patient outcomes
Penicillin
Pharmacological research
Pneumonia
Research Article
Staphylococcus aureus
Staphylococcus infections
Streptococcus infections
Streptococcus pneumoniae
Surveillance
Tetracyclines
Virology
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yIOqD-G2984gi-OAWu03z0cdV7jgFfVAP7i0kaXoW9tpjt4usf_3NpB9uFU4ffCiFZlI6H5nM0MlvCHmVesQlYjZ2NoUExUgbK8t47A23iRcFKwNOwafP4uQ0-3jGz3ZafWFNWAcP3AkOEvYkc4xZVqgim5dKWQg5pPUM28YIE7xvovIhmer_H0jIu4YjMkq8XYMXFlhsm-A1z2M12YYCWv-fPnlnU_q9YHL8a3qH3NrUl2b7wyyXOxvT8T1yt48o6aLj5D654esH5GbXY3L7kPxc1G11UQW8JSDDcwzYLoI2JW0uTGHcFg9HelrVFJ6vGmrOTQUxI7UdjrOhFZgnRKQFxaMoFBjLaNvgXeKk0IB7Rg0NpYkxfrtf0YBa-4icHh99e38S9w0XYieyeRs76TGBKEWmuBFM5KV13MkSogCQuhAQSngI71KXFg4SnRKCl5JbluSQZUrjcvaY7NVN7Z8SWijrpYR3eW4zyYVxXCkObzKw_0mrIjIf5K9dj0aOTTGWOmQlSuhOZxr0pYPONMx5M8657LA4rqV-h2odKRFHOzwA69K9dem_WVdEXqJRaETKqLEU59xs1mv94esXvRCIniZUDkSve6KyAR6c6U82gCQQXGtCeTChhKXspsOD7enelaw1Av4pbGIKHL0Yh3EmlsfVvtl0NCxHMLmIPOlMdeSbgZPFtDUicmLEE8FMR-rqewAal0JAdiAjMhvM_ddnXSf42bgk_kFPz_6HnvbJ7RRXN9ZnigOy1642_jlEi609DI7hClRMXv8
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA_nHqI-iN9WT4ki-OCW223aJH0Q2ZM7TsFFTg_uLSRpuhb22nU_kPWvdyb9uKvC4sOy0E5KJ5mZzDQzvyHkTeQQl4iZ0JoIAhQtTCgNS0KnEzNyPGO5xyn4MuWn5_Hni-Rij0zbWhhMq2xtojfUWWXxG_kh4p5J7OUoPyx-htg1Ck9X2xYaummtkL33EGM3yH6EyFgDsn90PP161p0rCIjH2tIZyQ9XYJ05JuGO8DdOQ9nbnjyK_7-2-tpm9XciZXeaeofc2pQLvf2l5_NrG9bJPXK38TTppBaN-2TPlQ_Izbr35PYh-T0BRi4Lj8MEZFjfgG0kaJXT6lJn2m6xaNLRoqRwfVlRPdMF-JLU1PjOmhYgtuCpZhRLVCgwFtN1hf8CB_nG3EOqqU9ZDPHd3ZJ6NNtH5Pzk-PvH07BpxBBaHo_XoRUOA4ucxzLRnPE0NzaxIgfvwIAGc3AxHLh9kY0yCwFQDk5Nnhg2SiH6FNqm7DEZlFXpnhKaSeOEgGe5xMQi4domUibwJA37ojAyION2_pVtUMqxWcZc-WhFclWvmYL1Un7NFIx5141Z1BgdO6mPcFk7SsTX9heq5Uw16qoSMYotY4ZlMovHuZTAJxPGMWxWxHUUkNcoFAoRNEpM0ZnpzWqlPn07UxOOqGpcpkD0tiHKK-DB6qbiAWYCQbd6lAc9SlBx27_dyp5qTMxKXSlEQF51t3Ekps2VrtrUNCxFkLmAPKlFteObgfHFcDYgoifEvYnp3ymLHx6AXHAOUYMIyLAV96vX2jXxw04l_mOdnu1m-jm5HaHeYkYmPyCD9XLjXoB_uDYvG6X_Az8NXgQ
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA96IuqD-G31lCiCD25x2zQffdw77jgFfVAP7i0kaXpX2GuP3S6y_vXOpN3e1pNDH0qhmYQmM8nMkJnfEPIu9YhLxGzsbAoOipE2Vpbx2Btup14UrAw4BV--iqPj7PMJP-lhcjAXZvv-PlHi4xLOT4FhslN8kjxWN8ktUFIiXMyK_eHGQIKntUmK-Wu_keIJ-PxXT-EtNfRniORwT3qP3FnVF2b908znW6ro8AG539uQdNYx_SG54etH5HZXVXL9mPya1W11XgWEJSDDzAUsEEGbkjbnpjBujemQnlY1he-LhppTU4GVSG2H3GxoBQIJNmhBMfmEwsQy2jb4ltgplNyeUENDMGKM_-4XNODUPiHHhwc_9o_ivsRC7ESWtLGTHl2GUmSKG8FEXlrHnSxB71vYmwKMBw8GXerSwoFrU4K5UnLLpjn4ldK4nD0lO3VT--eEFsp6KWEsz20muTCOK8VhJAMaT1oVkWSz_tr1-ONYBmOugx-ihO54poFfOvBMQ58PQ5-LDn3jWuo9ZOtAicjZ4QMIlO43ouZymjnGLCtUkSWlUjBPJq1nWIZImDQib1EoNGJj1Bh8c2pWy6X-9P2bngnESxMqB6L3PVHZwByc6XMZYCUQTmtEuTuihM3rxs0b2dP94bHUCPGnsGwpzOjN0Iw9MSCu9s2qo2E5wsdF5FknqsO8GRyr6KhGRI6EeLQw45a6OgvQ4lII8AdkRCYbcb_8resWfjJsiX_g04v_G_0luZviPsbYS7FLdtrFyr8CS7C1r8MR8BtSTlBM
  priority: 102
  providerName: Springer Nature
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9NAEF-0h6gPfp5aPWUVwQebXpvNfuSxiscpeIhaOJ-W3c2mhmuT0g-k99c7k6SxOeVQ8KGkZGeT7GTni8z8hpCXoUdcImYDZ0MIUIy0gbKMB95wO_AiYWmJU_DxRByPow-n_LRuB4S1MHbmZlkNQdTfrUCflmob_rizw3mSVtKuxOESFKzAPNoB_oZxoK6SPcHBMe-QvfHJp9G3sr5IDgMwZoNt2cwfJ7ZMU4ng_7ue3jFUF5Momy-pN8n1dT43mx9mOt0xVke3yXS7zCpH5ay_Xtm-O7-AAPmf-HCH3KqdWjqqduFdcsXn98i1qs3l5j45H-WrrL4PkGEpBXasoEVKi5lJjNtgfaanWU7h_KKgZmIycFupraCkDc1AQsApTihWw1C4cURXBR4lTip7gPeooWV2ZIAr8AtaAufuk_HRu69vj4O650PgRDRcBU56jGFSESluBBNxah13MgVHxIKyEODNePAwQxcmDmKtFPynlFs2iCHQlcbF7AHp5EXuHxGaKOulhGt5biPJhXFcKQ5XMmCCpVVdMty-bu1qQHTsyzHVZWCkhK54qoGfuuSphjmvmznzCg7kUuo3uIsaSoTyLk8Ui4muNYPmchA5xixLVBINU6VgnUxaz7AvkjBhl7zAPagRrCPHbKCJWS-X-v2Xz3okEMBNqBiIXtVEaYF7w9TFFcAJxPdqUR60KEGbuPbwdqvrWpstNWIOKuyjCit63gzjTMzQy32xrmhYjHh2XfKwkoxm3Qz0PEbOXSJbMtNiTHskz76XWOdSCAhQZJf0ttL167EuY3yvkcC_eE-P_438CbkRopxhMqg4IJ3VYu2fgmu6ss9qlfMTW8-CsA
  priority: 102
  providerName: Unpaywall
Title Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study
URI https://link.springer.com/article/10.1186/s12866-020-02019-8
https://www.ncbi.nlm.nih.gov/pubmed/33198626
https://www.proquest.com/docview/2461855618
https://www.proquest.com/docview/2461395568
https://pubmed.ncbi.nlm.nih.gov/PMC7667747
https://bmcmicrobiol.biomedcentral.com/track/pdf/10.1186/s12866-020-02019-8
https://doaj.org/article/5704c33b3d8d41f88b1937be359626a2
UnpaywallVersion publishedVersion
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMed Central Open Access Free
  customDbUrl:
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: RBZ
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: KQ8
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: KQ8
  dateStart: 20010201
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: DOA
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: ABDBF
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVEBS
  databaseName: EBSCOhost Food Science Source
  customDbUrl:
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: A8Z
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/login.aspx?authtype=ip,uid&profile=ehost&defaultdb=fsr
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: DIK
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: M~E
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central (PMC)
  customDbUrl:
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: RPM
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1471-2180
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: M48
  dateStart: 20010701
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: HAS SpringerNature Open Access 2022
  customDbUrl:
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: AAJSJ
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 1471-2180
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017837
  issn: 1471-2180
  databaseCode: C6C
  dateStart: 20010112
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELf2IQQ8IL4pjMogJB5ooK0T23lAqK02DaRVU6FS4cWyHadU6pKuH4Ly13PnpN0C07SHtkp8tnL2ne-uOf-OkDdth7hEzATWtCFA0cIE0rAocDoyTccTlnqcgpM-Px6GX0bRaIds0m3LCVxcGdphPanhfPr-9_n6Eyj8R6_wkn9YwB7LMZW2iZ9WDKs6Ow-wsBS-gC2rbOySfTBeMVZ3OAkvXjQI6WE1W7BHB2DtmptzNVcOW7FdHuL__438kiX7N8ty-6r1Lrm9ymZ6_UtPp5es2dF9cq90Q2mnkJsHZMdlD8mtojDl-hH508mWk7OJB2kCMjz8gDUmaJ7S_Ewn2q7xRKWjk4zC_XlO9VhPwNGkpgB_1nQCMg1ubELx_AoFxkK6zPFXYCdftbtBNfX5jAE-u5tTD3X7mAyPDr_1joOySkNgedhaBlY4jDpSHspIc8bj1NjIihRcBwPqzcH_cOATtm07sRAdpeDxpJFhzRhCU6FtzJ6QvSzP3DNCE2mcEDCWi0woIq5tJGUEI2kwmsLIGmlt5l_ZEsIcK2lMlQ9lJFfFmilYL-XXTEGfd9s-swLA41rqLi7rlhLBt_2NfD5WpS6rSDRDy5hhiUzCViol8MmEcQwrGXHdrpHXKBQK4TUyzN8Z69VioT5_HagOR8g1LmMgelsSpTnwYHV5HAJmAhG5KpQHFUrQf1tt3sie2qiPQpRAiZVPgaNX22bsiTl1mctXBQ2LEYGuRp4Worrlm8HOjLFujYiKEFcmptqSTX56dHLBOYQUokYaG3G_eKzrJr6xVYkbrNPzG3D1gtxpo_JiziY_IHvL-cq9BA9yaepkV4xEnex3D_unA7jq8V7d_xtT97sDfA-6P6B92D_tfP8LQpRtHw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemTWjwgPimMMAgEA80WhsntvMwoQ42rWyr0NikvRnbcUqlLin90FT-OP427vK1BaSKlz1UlZJzFPvO9xHf_Y6Qt75DXCJmPGt8CFC0MJ40LPScDk3H8ZglOU7B8YAfnAVfzsPzNfK7qoXBtMpKJ-aKOs4sfiPfRtwzib0c5cfJTw-7RuHpatVCQ5etFeKdHGKsLOw4dMtLCOFmO_3PwO93vr-_d_rpwCu7DHiWB925Z4VDrznhgQw1ZzxKjA2tSMD0GRBPDvbTgU_jWz-24N0nYLGT0LBOBKGV0BbBmMAEbAQsiCD429jdG3w9qc8xBMR_VamO5NszsAYck347-OtGnmyYw7xrwL-24Zpx_Dtxsz69vUM2F-lELy_1eHzNQO7fI3dLz5b2ClG8T9Zc-oDcKnpdLh-SXz1YuItRjvsEZFhPgW0raJbQ7ELH2i6xSNPRUUrh-jSjeqhH4LtSU-BJazqCbQKecUyxJIbCxAI6z_Bf4KC8EXibapqnSHr47m5Kc_TcR-TsRljymKynWeqeEhpL44SAZ7nQBCLk2oZShvAkDXZYGNki3Wr9lS1R0bE5x1jl0ZHkquCZAn6pnGcKxnyox0wKTJCV1LvI1poS8bzzC9l0qEr1oELRCSxjhsUyDrqJlDBPJoxj2ByJa79F3qBQKETsSDElaKgXs5nqfztRPY4oblxGQPS-JEoymIPVZYUFrASCfDUotxqUoFJs83Yle6pUaTN1tQFb5HV9G0diml7qskVBwyIEtWuRJ4Wo1vNmoOwxfG4R0RDixsI076SjHzngueAcohTRIu1K3K9ea9XCt-st8R98erZ60q_I5sHp8ZE66g8On5PbPu5hzAblW2R9Pl24F-Cbzs3LUgFQ8v2mdc4fR46ZIg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dj9MwDI_gEF8PiG8KBwSExAOrbmvaJH0cg-mOjxMCTrq3KEnTUWnXTlsnNP567LQrK6ATPFSVGieqEzuxFftnQl5EDnGJmAmticBB0cKE0rAkdDoxQ8czlnucgo_H_PAkfneanO5k8fto9-2VZJPTgChNZX2wyPJGxSU_WMGuyjF4dojPKA3lRXIphtMNaxhM-KS7RxDgf21TZf7ar3ccedT-P_fmncPp98DJ7vb0Orm6Lhd6813P5zsH1PQmudFalnTciMItcsGVt8nlptbk5g75MS7r4qzwuEtAhvkMWDaCVjmtznSm7QaTJB0tSgrflxXVM12A7UhNg-esaQFiCpZpRjElhQJjMa0rfAvs5AtxD6imPkQxxH93S-rRa--Sk-nbr5PDsC28EFoej-rQCoeORM5jmWjOeJobm1iRgzVgQGM5mBQOzLzIRpkFhycHIyZPDBum4G0KbVN2j-yVVekeEJpJ44SAsVxiYpFwbRMpExhJwzkojAzIaDv_yrao5FgcY668dyK5atZMwXopv2YK-rzq-iwaTI5zqV_jsnaUiKftP1TLmWrVUyViGFvGDMtkFo9yKYFPJoxjWJyI6yggz1EoFCJmlBiSM9Pr1UodffmsxhxR1LhMgehlS5RXwIPVbYYDzASCbPUo93uUoNK237yVPdVuKSuFwH8Si5kCR8-6ZuyJYXKlq9YNDUsRVC4g9xtR7fhmsNmi-xoQ0RPi3sT0W8rimwccF5yDlyACMtiK-6_fOm_iB51K_MM6Pfy_0Z-SK5_eTNWHo-P3j8i1CFUagzP5Ptmrl2v3GEzF2jzxu8FPWIlbgg
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9NAEF-0h6gPfp5aPWUVwQebXpvNfuSxiscpeIhaOJ-W3c2mhmuT0g-k99c7k6SxOeVQ8KGkZGeT7GTni8z8hpCXoUdcImYDZ0MIUIy0gbKMB95wO_AiYWmJU_DxRByPow-n_LRuB4S1MHbmZlkNQdTfrUCflmob_rizw3mSVtKuxOESFKzAPNoB_oZxoK6SPcHBMe-QvfHJp9G3sr5IDgMwZoNt2cwfJ7ZMU4ng_7ue3jFUF5Momy-pN8n1dT43mx9mOt0xVke3yXS7zCpH5ay_Xtm-O7-AAPmf-HCH3KqdWjqqduFdcsXn98i1qs3l5j45H-WrrL4PkGEpBXasoEVKi5lJjNtgfaanWU7h_KKgZmIycFupraCkDc1AQsApTihWw1C4cURXBR4lTip7gPeooWV2ZIAr8AtaAufuk_HRu69vj4O650PgRDRcBU56jGFSESluBBNxah13MgVHxIKyEODNePAwQxcmDmKtFPynlFs2iCHQlcbF7AHp5EXuHxGaKOulhGt5biPJhXFcKQ5XMmCCpVVdMty-bu1qQHTsyzHVZWCkhK54qoGfuuSphjmvmznzCg7kUuo3uIsaSoTyLk8Ui4muNYPmchA5xixLVBINU6VgnUxaz7AvkjBhl7zAPagRrCPHbKCJWS-X-v2Xz3okEMBNqBiIXtVEaYF7w9TFFcAJxPdqUR60KEGbuPbwdqvrWpstNWIOKuyjCit63gzjTMzQy32xrmhYjHh2XfKwkoxm3Qz0PEbOXSJbMtNiTHskz76XWOdSCAhQZJf0ttL167EuY3yvkcC_eE-P_438CbkRopxhMqg4IJ3VYu2fgmu6ss9qlfMTW8-CsA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antimicrobial+activity+of+omadacycline+in+vitro+against+bacteria+isolated+from+2014+to+2017+in+China%2C+a+multi-center+study&rft.jtitle=BMC+microbiology&rft.au=Xiao%2C+Meng&rft.au=Huang%2C+Jing-Jing&rft.au=Zhang%2C+Ge&rft.au=Yang%2C+Wen-Hang&rft.date=2020-11-16&rft.issn=1471-2180&rft.eissn=1471-2180&rft.volume=20&rft.issue=1&rft.spage=350&rft_id=info:doi/10.1186%2Fs12866-020-02019-8&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2180&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2180&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2180&client=summon